Unknown

Dataset Information

0

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.

ABSTRACT: Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.

SUBMITTER: Xie X 

PROVIDER: S-EPMC7805448 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.

Xie Xuping X   Zou Jing J   Fontes-Garfias Camila R CR   Xia Hongjie H   Swanson Kena A KA   Cutler Mark M   Cooper David D   Menachery Vineet D VD   Weaver Scott S   Dormitzer Philip R PR   Shi Pei-Yong PY  

bioRxiv : the preprint server for biology 20210107

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N5  ...[more]

Similar Datasets

Unknown Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
| S-EPMC7814835 | biostudies-literature
Unknown Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera.
| S-EPMC7852264 | biostudies-literature
Unknown The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.
| S-EPMC7994717 | biostudies-literature
Unknown Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.
| S-EPMC8754807 | biostudies-literature
Unknown BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
| S-EPMC8133696 | biostudies-literature
Unknown SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
| S-EPMC8461567 | biostudies-literature
Unknown Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians.
| S-EPMC8450274 | biostudies-literature
Unknown Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
| S-EPMC7891044 | biostudies-literature
Unknown Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
| S-EPMC8541826 | biostudies-literature
Unknown SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster.
| S-EPMC8722594 | biostudies-literature